GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed ...
European shares trimmed morning gains on Wednesday as continuing geopolitical tensions in Ukraine hit sentiment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback